2026/08/18 更新

お知らせ

 

写真a

ヨシタケ タダマサ
吉武 忠正
YOSHITAKE TADAMASA
所属
医学研究院 准教授
九州大学病院 放射線科(併任)
職名
准教授
連絡先
メールアドレス
電話番号
0926425695
プロフィール
(診療) 九州大学病院にて放射線治療専門医として、放射線治療業務全般を行っている。 外来:放射線治療の新患患者の対応(診察、放射線治療の説明、検査説明など)、放射線治療中患者の診察、治療後患者の経過観察を行っている。 入院:入院患者の回診、治療方針の検討、入院主治医や担当医への指導を行っている。 放射線治療業務:放射線治療として、通常放射線治療に加えて、定位放射線治療、強度変調放射線治療などの高精度放射線治療を行っている。 (研究) ・体幹部定位放射線治療についての研究を行っている。 ・脳転移の放射線治療方針についての研究を行っている。 ・AIによる骨盤内リンパ節領域抽出についての研究を行っている。 (教育) 医学部学生や大学院生に対して放射線治療に関する講義を行っている(1年に6コマ) (管理) 医局長として医局運営を行っている(令和4年度) 部会長として原発不明がん部会を開催している(2ヶ月に1回) また、脳腫瘍部会(1ヶ月に1回)、多臓器癌部会(週1回)、口腔癌部会(月1回)などに参加している。
ホームページ
外部リンク

学位

  • 医学博士

研究テーマ・研究キーワード

  • 研究テーマ: 悪性腫瘍に対する即時適応放射線治療の有用性の検証

    研究キーワード: 即時適応放射線治療

    研究期間: 2022年4月 - 2027年3月

  • 研究テーマ: 同時化学放射線療法を受けた局所進行非小細胞肺癌の症例検索システム開発 CRT case library study

    研究キーワード: radiotherapy

    研究期間: 2021年11月 - 2022年6月

  • 研究テーマ: 放射線治療用臓器抽出エンジンの開発に向けた、放射線治療データ収集

    研究キーワード: 放射線治療、AI、自動抽出

    研究期間: 2019年12月 - 2021年3月

  • 研究テーマ: 脳腫瘍に対する放射線治療

    研究キーワード: 脳腫瘍、放射線治療

    研究期間: 2015年6月 - 2021年3月

  • 研究テーマ: 肺癌に対する体幹部定位照射に関する臨床研究

    研究キーワード: 定位照射、肺癌

    研究期間: 2010年4月 - 2013年3月

受賞

  • 日本放射線腫瘍学会第19回学術大会 優秀発表賞(総合)

    2006年11月   日本放射線腫瘍学会   画像処理システムによる視覚フィードバックを用いた呼吸停止法の開発

論文

  • Transvaginal approach combined intracavitary and interstitial brachytherapy assisted by transrectal ultrasound: results from 30 patients with locally advanced cervical cancer 査読 国際誌

    Nakashima, T; Matsumoto, K; Yoshitake, T; Wakiyama, H; Hisano, O; Uehara, R; Takaki, M; Oshima, T; Yahata, H; Ishigami, K

    JAPANESE JOURNAL OF RADIOLOGY   42 ( 1 )   96 - 101   2023年8月   ISSN:1867-1071 eISSN:1867-108X

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Japanese Journal of Radiology  

    Purpose: This study evaluated the efficacy and safety of transvaginal approach combined intracavitary and interstitial brachytherapy (IC/IS BT) assisted by transrectal ultrasound (TRUS) for treatment of locally advanced cervical cancer (LACC). Materials and Methods: A total of 30 patients of LACC treated with external beam radiotherapy and IC/IS BT via transvaginal approach assisted by transrectal ultrasound were observed retrospectively. The 2-year local control (LC), progression-free survival (PFS), and overall survival (OS) were analyzed using the Kaplan–Meier method. Late adverse events were also evaluated to assess the safety of IC/IS BT. Results: The median follow-up period was 22 months. The 2-year LC, PFS, and OS were 90%, 61%, and 82%, respectively. We observed no critical complications related to the IC/IS BT technique. Late adverse events of grade 3 or more included one case of grade 4 colon perforation. Conclusion: Our patient series demonstrated that radiotherapy combined with transvaginal approach, TRUS-assisted IC/IS BT achieves favorable local control and safety for LACC.

    DOI: 10.1007/s11604-023-01481-4

    Web of Science

    Scopus

    PubMed

  • Stereotactic body radiotherapy to treat small lung lesions clinically diagnosed as primary lung cancer by radiological examination: A prospective observational study. 査読

    Inoue T, Katoh N, Ito YM, Kimura T, Nagata Y, Kuriyama K, Onishi H, @Yoshitake T, @Shioyama Y, Iizuka Y, Inaba K, Konishi K, Kokubo M, Karasawa K, Kozuka T, Tanaka K, Sakakibara-Konishi J, Kinoshita I, Shirato H.

    Lung Cancer   2018年8月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Breath-hold monitoring and visual feedback for radiotherapy using a charge-coupled device camera and a head-mounted display: system development and feasibility. 査読 国際誌

    Yoshitake T, Nakamura K, Shioyama Y, Nomoto S, Ohga S, Toba T, Shiinoki T, Anai S, Terashima H, Kishimoto J, Honda H

    Radiat Med   26 ( 1 )   2011年7月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • A clinical evaluation of visual feedback-guided breath-hold reproducibility of tumor location 査読 国際誌

    Yoshitake T, Shioyama Y, Nakamura K, Ohga S, Nonoshita T, Ohnishi K, Terashima K, Arimura H, Hirata H, Honda H

    Phys Med Biol   54 ( 23 )   2009年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial 査読 国際誌

    Nagumo Y., Kimura T., Ishikawa H., Sekino Y., Maruo K., Mathis B.J., Kageyama Y., Ushijima H., Kamei J., Yamashita H., Azuma H., Nihei K., Naiki T., Tomita N., Kobayashi Y., Yoshio K., Matsumoto T., Yoshitake T., Osawa T., Nishioka K., Kita Y., Mizowaki T., Hattori K., Tsuzuki T., Hashimoto K., Nishiyama H.

    European Urology   2026年   ISSN:03022838

     詳細を見る

    記述言語:英語   出版者・発行元:European Urology  

    Radical cystectomy (RC) is the standard care for muscle-invasive or very high-risk non–muscle-invasive bladder cancer (BC), but optimal management for bladder preservation remains uncertain. In this multicentre, open-label, phase 2 trial, patients with cT1–3 N0 M0 muscle-invasive BC received radiation therapy (RT; 41.4 Gy to the small pelvis and 16.2 Gy to the whole bladder) and atezolizumab (1200 mg) every 3 wk. The primary endpoint was progression-free survival (PFS) at 3 yr. Key secondary endpoints included the clinical complete response (cCR) rate at 24 wk, overall survival (OS), and the bladder-intact recurrence-free rate (BIRFR). From 2019 to 2021, 41 of the 45 patients enrolled received treatment. The median age was 71 yr and most patients (73%) had T2 tumours. At 24 wk, 84% achieved cCR. The 3-yr PFS rate was 70% (95% confidence interval [CI] 54–81%), with the lower limit of the 95% CI exceeding the prespecified threshold of 45%. The 3-yr OS rate was 91% and the 3-yr BIRFR was 89%. Grade ≥3 adverse events occurred in 55% of patients, but no treatment-related deaths were observed. Limitations include the single-arm design and cohort size. Bladder preservation therapy with atezolizumab and RT showed favourable treatment effects with manageable toxicity for patients unfit for or refusing RC.

    DOI: 10.1016/j.eururo.2025.12.019

    Scopus

    PubMed

  • Impact of high-dose pelvic radiotherapy combined with chemotherapy on local control, symptom relief, and safety in patients with stage IVB cervical cancer (FIGO 2018): a two-center retrospective study 査読 国際誌

    Nakashima, T; Matsumoto, K; Yoshitake, T; Kunitake, N; Abe, M; Ariyoshi, K; Yahata, H; Ishigami, K

    JAPANESE JOURNAL OF RADIOLOGY   2025年12月   ISSN:1867-1071 eISSN:1867-108X

     詳細を見る

    記述言語:英語   出版者・発行元:Japanese Journal of Radiology  

    Purpose: This study evaluated the efficacy and safety of high-dose pelvic radiotherapy combined with chemotherapy, including bevacizumab and immune checkpoint inhibitors (ICI) in patients with stage IVB cervical cancer (CC) based on the 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging system. Materials and methods: A retrospective analysis was conducted on 38 patients with stage IVB CC, as classified by the 2018 FIGO cervical cancer staging system, who received pelvic external beam radiotherapy (≥ 40 Gy) with or without brachytherapy and chemotherapy. Data were collected from two centers. The 2-year local control (LC), progression-free survival (PFS), and overall survival (OS) rates were analyzed using the Kaplan–Meier method. Symptom relief, including reductions in genital bleeding and pain from the primary lesion, was assessed. Acute and late adverse events were also evaluated. Results: The median follow-up period was 17.5 months. The 2-year LC, PFS, and OS were 82%, 11%, and 47%, respectively. Although the evaluation method has limitations, most patients with genital bleeding and pain from the primary lesion showed improvement in symptoms. Late adverse events of grade ≥ 2 related to both pelvic radiotherapy and bevacizumab included one case of grade 3 gastrointestinal bleeding and two cases of grade 2 fistula. Conclusion: This two-center study demonstrated that high-dose pelvic radiotherapy combined with chemotherapy, including bevacizumab and ICI, may achieve favorable local control and symptom relief in patients with stage IVB CC while maintaining an acceptable safety profile.

    DOI: 10.1007/s11604-025-01923-1

    Web of Science

    Scopus

    PubMed

  • 特集 がん放射線療法--最新治療技術とエビデンス 切らない高精度放射線治療がAIでさらなる高みへ

    有村 秀孝, 金 煜, 吉武 忠正

    医学のあゆみ   295 ( 11 )   1075 - 1082   2025年12月   ISSN:00392359

     詳細を見る

    出版者・発行元:医歯薬出版  

    DOI: 10.32118/ayu295111075

    CiNii Research

  • 【がん放射線療法-最新治療技術とエビデンス】切らない高精度放射線治療がAIでさらなる高みへ

    有村 秀孝, 金 いく, 吉武 忠正

    医学のあゆみ   295 ( 11 )   1075 - 1082   2025年12月   ISSN:0039-2359

     詳細を見る

    記述言語:日本語   出版者・発行元:医歯薬出版(株)  

    <文献概要>放射線治療は患者の体を切らない局所治療で,機能・形態温存と非侵襲性の利点がある.放射線治療の主な適応は,中枢神経,頭頸部,胸部,消化器,泌尿器,婦人科領域,血液,リンパ,皮膚,骨・軟部組織,疼痛緩和,良性疾患であり,臓器横断的に適用可能である.放射線治療の目的は,非侵襲的に腫瘍領域に十分な線量を投与し,腫瘍に近接するリスク臓器(放射線感受性の高い臓器)を含む正常組織には線量をできるだけ減らすことである.この目的のために非侵襲的画像を用いた放射線治療が標準となっている.画像情報を学習できるAI(人工知能)との親和性は高く,切らない高精度放射線治療がAIを応用することで,さらなる高みを目指せる可能性が高い.本稿では,AIが放射線治療へ貢献できること,つまり治療方針決定支援,腫瘍とリスク臓器の輪郭抽出支援,治療計画支援,治療実施支援,フォローアップ支援および予後予測支援を概説し,最後に未来の高精度放射線治療を予測する.

  • Dosimetric evaluation of cone beam computed tomography-guided online adaptive radiotherapy in gastric mucosa-associated lymphoid tissue lymphoma 査読

    Takaki, M; Hirose, TA; Yoshitake, T; Matsumoto, K; Shirakawa, Y; Wakiyama, H; Hisano, O; Imafuku, H; Ishigami, K

    TECHNICAL INNOVATIONS & PATIENT SUPPORT IN RADIATION ONCOLOGY   35   100321   2025年9月   eISSN:2405-6324

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Technical Innovations and Patient Support in Radiation Oncology  

    Introduction: This study evaluated dosimetric values of cone beam computed tomography (CBCT)-guided online adaptive radiotherapy (oART) in patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma, accounting for interfractional and intrafractional motion. Methods: Four patients with stage I gastric MALT lymphoma received CBCT-guided oART. For each of the 60 treatment sessions, scheduled (SCH) and adapted (ADP) plans were generated. Dosimetric evaluation focused on clinical target volume (CTV) and organs at risk (OARs). Metrics included CTV D98 % and D95 %, mean dose to the liver and left and right kidneys, maximum dose to the spinal cord, and V5Gy for bilateral kidneys. Adaptive planning CBCT-based contours were propagated to synthetic CTs of SCH and ADP plans to assess interfractional motion. Post-treatment CBCT-based contours were propagated to synthetic CTs of the ADP plan to evaluate intrafractional motion. Results: ADP plans significantly improved CTV coverage: mean D98% increased from 94.7 % in the SCH plan to 98.6 %, and D95% from 97.3 % to 99.2 % (p < 0.001). Most OAR doses were reduced in the ADP plans, including bilateral kidney V5Gy (11.3 % vs. 8.3 %, p < 0.001) and spinal cord Dmax (9.8 Gy vs. 7.9 Gy, p < 0.001). Liver Dmean was slightly higher in the ADP plan (11.4 Gy vs. 11.1 Gy, p = 0.002). No significant differences were observed in CTV and OAR dosimetric parameters between adaptive planning and post-treatment CBCTs (e.g., CTV D98%: 98.6 % vs. 98.5 %, p = 0.629). Conclusion: CBCT-guided oART improved target coverage and maintained post-treatment dosimetric stability in gastric MALT lymphoma, supporting clinical feasibility.

    DOI: 10.1016/j.tipsro.2025.100321

    Web of Science

    Scopus

    PubMed

  • Time-variant tumor growth trajectory models for in silico randomized controlled trials for patients with early-stage non-small cell lung cancer in optimizing stereotactic body radiation therapy 査読 国際誌

    Mitsushima, K; Arimura, H; Shirakawa, Y; Kodama, T; Yoshitake, T

    HEALTH AND TECHNOLOGY   15 ( 5 )   963 - 973   2025年8月   ISSN:2190-7188 eISSN:2190-7196

     詳細を見る

    担当区分:最終著者   記述言語:英語   出版者・発行元:Health and Technology  

    Purpose: Applying new treatments to real patients to verify therapeutic efficacy may induce various risks, such as critical adverse events. Additionally, there are ethical and financial issues in real-world randomized controlled trials (RCTs). This study aimed to develop mathematical models of time-variant tumor growth trajectories (TGTs) for in silico RCTs targeting patients with stage I non-small cell lung cancer (NSCLC) to optimize stereotactic body radiation therapy (SBRT). Methods: The basic idea of the in silico RCT was to evaluate the endpoint of progression-free survival (PFS) curves for the two regimens derived from TGTs for virtual patient data produced via mathematical models. TGT models with a relative number of tumor cells were proposed by integrating the Bertalanffy-Pütter (BP) model and linear quadratic model into tumor growth models. To validate the proposed models, we performed three RCTs, 30 Gy/1 fraction (Fr) versus 60 Gy/3 Fr, 48 Gy/4 Fr versus 75 Gy/25 Fr, and 34 Gy/1 Fr versus 48 Gy/4 Fr. Results: The three in silico RCTs showed no statistically significant differences in PFS curves, which was similar to the results of three previous studies. Conclusions: The proposed mathematical models could be leveraged for in silico RCTs to optimize SBRT.

    DOI: 10.1007/s12553-025-01005-2

    Web of Science

    Scopus

  • Can Online Adaptive Radiation Therapy Eliminate Intrafractional Deformation in Gastric Mucosa-Associated Lymphoid Tissue Lymphoma? 査読 国際誌

    Shibayama Y., Arimura H., Hirose T.a., Takaki M., Fukunaga J.i., Yoshitake T., Kato T., Ishigami K.

    Practical Radiation Oncology   15 ( 6 )   e621 - e633   2025年6月   ISSN:18798500

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Practical Radiation Oncology  

    Purpose: We hypothesized that online adaptive radiation therapy (oART) could eliminate errors associated with interfractional deformation in gastric mucosa-associated lymphoid tissue (MALT) lymphoma, but errors in intrafractional deformation remained in 6 directions (anterior, posterior, superior, inferior, left, and right). This study aimed to quantify the anisotropic deformation errors of the clinical target volume (CTV) for MALT lymphoma using oART to determine deformations in the planning target volume (PTV) margins. Methods and Materials: Thirty fractional scans from 4 consecutive patients (a total of 120 cone beam computed tomography scans) with gastric MALT lymphoma treated with oART were chosen for this retrospective study. The CTV contours were manually delineated on the pretreatment and posttreatment cone beam computed tomography images. The center-of-mass matching of the CTVs was performed following the bone anatomy matching. Systematic and random errors of intrafractional deformations of the CTV were quantified using displacement vectors between the pretreatment and posttreatment CTV surfaces for each fraction. The PTV margins for oART were anisotropically calculated using the van Herk formula: 2.5Σ + 0.7σ, accounting for intrafractional errors. Results: For intrafractional deformation, the means of standard deviations of systematic errors ranged from 1.2 mm to 2.2 mm, whereas those of random errors ranged from 2.9 mm to 3.6 mm. The PTV margins were up to 13.1 mm in the inferior direction, whereas in other directions, they ranged from 9.7 mm to 12.8 mm. The PTV margin in integer achieved posttreatment CTV coverage for 90% of the fractions, with undercoverage volumes remaining below 0.6 cm<sup>3</sup> in all fractions. Conclusions: This study suggests that the impact of intrafractional CTV deformation can not be eliminated even with oART. This highlights the need to set the appropriate anisotropic PTV margins.

    DOI: 10.1016/j.prro.2025.05.008

    Web of Science

    Scopus

    PubMed

  • A single-arm confirmatory trial of postoperative CCRT using IMRT for patients with high-risk uterine cervical cancer (JCOG1402) 査読

    Isohashi, F; Toita, T; Kobayashi, H; Kasamatsu, T; Machida, R; Murakami, N; Hasumi, Y; Okamoto, H; Ishikura, S; Ushijima, H; Horie, K; Tsujino, K; Togami, S; Tanigawa, M; Nishio, H; Takada, T; Konishi, K; Ariyoshi, K; Konish, K; Yoshitake, T; Nakamura, K; Saji, H; Hisa, T; Satoh, T; Mizowaki, T

    RADIOTHERAPY AND ONCOLOGY   206   S801 - S802   2025年5月   ISSN:0167-8140 eISSN:1879-0887

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

  • 深層学習に基づく放射線治療を受けた肺がん患者の治療計画CT画像におけるConsolidation/Tumor 比の自動予測 査読

    崔 雲昊, 有村 秀孝, 吉武 忠正, 佟 弈志, 兒玉 拓巳, 塩山 善之, Wirestam Ronnie, 薮内 英剛

    医用画像情報学会雑誌   42 ( 1 )   xxxv - xxxvi   2025年3月   ISSN:09101543 eISSN:18804977

     詳細を見る

    記述言語:日本語   出版者・発行元:医用画像情報学会  

    DOI: 10.11318/mii.42.xxxv

    CiNii Research

  • 【泌尿器腫瘍の最新の診断と治療】前立腺がんの治療 放射線治療

    中村 和正, 小西 憲太, 高木 正統, 吉武 忠正

    臨牀と研究   102 ( 2 )   138 - 142   2025年2月   ISSN:0021-4965

     詳細を見る

    記述言語:日本語   出版者・発行元:大道学館出版部  

  • A case of malignant spindle cell tumor of skull with BRAF V600E mutation 査読

    Tsuchihashi, K; Nishiyori, S; Kusumoto, Y; Yoshihiro, T; Arimizu, K; Sangatsuda, Y; Komune, N; Hisano, O; Yoshitake, T; Hazama, H; Mori, T; Yoshimoto, K; Oda, Y; Akashi, K; Baba, E

    CANCER SCIENCE   116   380 - 380   2025年1月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

  • 長期の治療経過中に硬膜転移を来した消化管間質腫瘍の1例 査読

    麦田 史仁, 三月田 祐平, 秦 暢宏, 沖 英次, 吉武 忠正, 山元 英崇, 吉本 幸司

    脳神経外科速報   34 ( 6 )   e179 - e187   2024年11月   ISSN:0917-1495

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:(株)メディカ出版  

    症例は40歳代女性で、頭痛、嘔吐、失語を主訴とした。15年前より小腸原発の消化管間質腫瘍(GIST)の治療中であり、主訴にて紹介入院し、頭部単純CTでは左中頭蓋窩に強い造影効果を伴う境界明瞭な高吸収域(48×36×47mm)と左前頭部の傍矢状洞部の病変(最大径14mm大)を認めた。MRIではT1で低信号から等信号、T2で等信号から高信号を呈する腫瘍と、腫瘍内のflow void、左中硬膜動脈の拡張、左側頭葉の広範な浮腫性変化、右側へ13mmの正中偏位と鉤ヘルニアを認め、入院2日目に開頭腫瘍摘出術を行った。術中迅速病理検査ではGISTの頭蓋内転移と診断され、病理標本と過去の肝転移標本の組織所見からGISTの脳転移と診断した。術後、失名詞失語症状は経時的に改善したが、術後8ヵ月目に局所再発をきたし、再手術後にも頭蓋内病変の再発を認め、頭蓋内転移診断後のOSは19ヵ月であった。

  • Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer 査読

    Shibahara D., Tanaka K., Togao O., Shiraishi Y., Yoneshima Y., Iwama E., Yoshitake T., Ishigami K., Okamoto I.

    Clinical Lung Cancer   25 ( 6 )   581 - 586.e3   2024年9月   ISSN:15257304

     詳細を見る

    記述言語:英語   出版者・発行元:Clinical Lung Cancer  

    The incidence of brain radiation necrosis is increasing in NSCLC patients undergoing radiotherapy for brain metastases. • [11C] methionine–PET and MRS are valuable tools for diagnosing brain radiation necrosis. • Bevacizumab is an effective treatment for brain radiation necrosis in patients with nonsquamous NSCLC.

    DOI: 10.1016/j.cllc.2024.06.010

    Scopus

    PubMed

  • Hemizygous deletion of cyclin-dependent kinase inhibitor 2A/B with p16 immuno-negative and methylthioadenosine phosphorylase retention predicts poor prognosis in IDH-mutant adult glioma 査読

    Otsuji, R; Hata, N; Yamamoto, H; Kuga, D; Hatae, R; Sangatsuda, Y; Fujioka, Y; Noguchi, N; Sako, A; Togao, O; Yoshitake, T; Nakamizo, A; Mizoguchi, M; Yoshimoto, K

    NEURO-ONCOLOGY ADVANCES   6 ( 1 )   vdae069   2024年7月   eISSN:2632-2498

     詳細を見る

    記述言語:英語   出版者・発行元:Neuro-Oncology Advances  

    Background. Homozygous deletion of the tumor suppression genes cyclin‑dependent kinase inhibitor 2A/B (CDKN2A/B) is a strong adverse prognostic factor in IDH‑mutant gliomas, particularly astrocytoma. However, the impact of hemizygous deletion of CDKN2A/B is unknown. Furthermore, the influence of CDKN2A/B status in IDH‑ mutant and 1p/19q‑codeleted oligodendroglioma remains controversial. We examined the impact of CDKN2A/B status classification, including hemizygous deletions, on the prognosis of IDH‑mutant gliomas. Methods. We enrolled 101 adults with IDH‑mutant glioma between December 2002 and November 2021. CDKN2A/B deletion was evaluated with multiplex ligation‑dependent probe amplification (MLPA). Immunohistochemical anal‑ ysis of p16/MTAP and promoter methylation analysis with methylation‑specific MLPA was performed for cases with CDKN2A/B deletion. Kaplan − Meier plots and Cox proportion hazards model analyses were performed to evaluate the impact on overall (OS) and progression‑free survival. Results. Of 101 cases, 12 and 4 were classified as hemizygous and homozygous deletion, respectively. Immunohistochemistry revealed p16‑negative and MTAP retention in cases with hemizygous deletion, whereas homozygous deletions had p16‑negative and MTAP loss. In astrocytoma, OS was shorter in the order of homozy‑ gous deletion, hemizygous deletion, and copy‑neutral groups (median OS: 38.5, 59.5, and 93.1 months, respec‑ tively). Multivariate analysis revealed hazard ratios of 9.30 (P = .0191) and 2.44 (P = .0943) for homozygous and hemizygous deletions, respectively. Conclusions. CDKN2A/B hemizygous deletions exerted a negative impact on OS in astrocytoma. Immunohistochemistry of p16/MTAP can be utilized to validate hemizygous or homozygous deletions in combina‑ tion with conventional molecular diagnosis.

    DOI: 10.1093/noajnl/vdae069

    Web of Science

    Scopus

    PubMed

  • 胃粘膜関連リンパ組織リンパ腫に対するCBCTベースオンライン適応放射線治療でのPTVマージンの評価(Evaluation of PTV margin in CBCT-based online adaptive radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma) 査読 国際誌

    Hirose Taka-aki, Takaki Masanori, Shibayama Yusuke, Fukunaga Jun-ichi, Kato Toyoyuki, Yoshitake Tadamasa, Ishigami Kousei

    Journal of Radiation Research   65 ( 4 )   507 - 511   2024年7月   ISSN:0449-3060

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本放射線影響学会  

    胃粘膜関連リンパ組織(MALT)リンパ腫に対し、オンライン適応放射線治療(oART)における計画標的体積(PTV)マージンについて検討した。2023年9~12月までの期間内に、当院で30Gy/15分割のoARTが施行された胃MALTリンパ腫患者4例を対象に、治療前後に得たコーンビームCT画像を用いて、分割照射中および分割照射間の胃の移動を評価した。なお、PTVマージンは分割照射中および分割照射間の移動をカバーする分割照射の累積比率から推定し、分割照射90%の臨床標的体積(CTV)をカバーする拡大範囲をPTVマージンとした。その結果、oARTを用いた場合の息止めによる分割照射中移動のPTVマージンは14mmであったが、oARTを用いない場合は25mmであった。以上の結果から、oARTによりPTVマージンを10mm超減少できることが確認された。

  • Evaluation of PTV margin in CBCT-based online adaptive radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma 査読

    Hirose, TA; Takaki, M; Shibayama, Y; Fukunaga, JI; Kato, T; Yoshitake, T; Ishigami, K

    JOURNAL OF RADIATION RESEARCH   65 ( 4 )   507 - 511   2024年6月   ISSN:0449-3060 eISSN:1349-9157

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Journal of Radiation Research  

    The aim of this study was to investigate planning target volume (PTV) margin in online adaptive radiation therapy (oART) for gastric mucosa-associated lymphoid tissue (MALT) lymphomas. Four consecutive patients with gastric MALT lymphoma who received oART (30 Gy in 15 fractions) on the oART system were included in this study. One hundred and twenty cone-beam computed tomography (CBCT) scans acquired pre- and post-treatment of 60 fractions for all patients were used to evaluate intra- and interfractional motions. Patients were instructed on breath-holding at exhalation during image acquisition. To assess the intrafraction gastric motion, different PTVs were created by isotropically extending the CTV contoured on a pre-CBCT image (CTVpre) at1 mm intervals. Intrafraction motion was defined as the amount of expansion covering the contoured CTV on post-CBCT images (CTVpost). Interfractional motion was defined as the amount of reference CTV expansion that could cover each CTVpre, as well as the evaluation of the intrafractional motion. PTV margins were estimated from the cumulative proportion of fraction covering the intra- and interfractional motions. The extent of expansion covering the CTVs in 90% of fractions was adopted as the PTV margin. The PTV margin for intrafractional gastric motion using the oART system with breath-holding was 14 mm. In contrast, the PTV margin for interfractional gastric organ motion without the oART system was 25 mm. These results indicated that the oART system can reduce the PTV margin by >10 mm. Our results could be valuable data for oART cases.

    DOI: 10.1093/jrr/rrae052

    Web of Science

    Scopus

    PubMed

  • Prediction of Consolidation Tumor Ratio on Planning CT Images of Lung Cancer Patients Treated with Radiotherapy Based on Deep Learning 査読

    Tong, YZ; Arimura, H; Yoshitake, T; Cui, YH; Kodama, T; Shioyama, Y; Wirestam, R; Yabuuchi, H

    APPLIED SCIENCES-BASEL   14 ( 8 )   2024年4月   eISSN:2076-3417

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Applied Sciences (Switzerland)  

    This study aimed to propose an automated prediction approach of the consolidation tumor ratios (CTRs) of part-solid tumors of patients treated with radiotherapy on treatment planning computed tomography images using deep learning segmentation (DLS) models. For training the DLS model for cancer regions, a total of 115 patients with non-small cell lung cancer (NSCLC) who underwent stereotactic body radiation therapy were selected as the training dataset, including solid, part-solid, and ground-glass opacity tumors. For testing the automated prediction approach of CTRs based on segmented tumor regions, 38 patients with part-solid tumors were selected as an internal test dataset A (IN) from a same institute as the training dataset, and 49 patients as an external test dataset (EX) from a public database. The CTRs for part-solid tumors were predicted as ratios of the maximum diameters of solid components to those of whole tumors. Pearson correlations between reference and predicted CTRs for the two test datasets were 0.953 (IN) and 0.926 (EX) for one of the DLS models (p < 0.01). Intraclass correlation coefficients between reference and predicted CTRs for the two test datasets were 0.943 (IN) and 0.904 (EX) for the same DLS models. The findings suggest that the automated prediction approach could be robust in calculating the CTRs of part-solid tumors.

    DOI: 10.3390/app14083275

    Web of Science

    Scopus

  • Efficacy and Safety of Adjuvant Radiotherapy for Soft Tissue Sarcoma: A Two-Institution Retrospective Observational Study 査読 国際誌

    久野 修, 吉武 忠正, ノモト サトシ, 松本 圭司, 脇山 浩明, 上原 隆治, 髙木 正統, 大島 健史, マツモト ヨシヒロ, 遠藤 誠, 鍋島 央, マツノブ トモヤ, マエカワ アキラ, 石神 康生

    SN Comprehensive Clinical Medicine   6 ( 1 )   2024年2月   eISSN:25238973

     詳細を見る

    記述言語:英語   出版者・発行元:Springer  

    The recommended post-operative radiotherapy dose of approximately 60 Gy may be reduced during treatment planning, and the optimal irradiation method and dose remain unclear. We aimed to clarify the usefulness and safety of post-operative radiotherapy for soft tissue sarcomas. Forty-five patients with soft-tissue sarcomas who underwent adjuvant radiotherapy at two institutions from June 2014 to August 2020 were included. Patients with a high risk of recurrence underwent post-operative irradiation, with doses of 60–70 Gy and 50 Gy used in patients with positive and negative resection margins, respectively. The median patient age was 72 (21–88) years. The most common histological types of sarcomas were myxofibrosarcoma (n = 12) and dedifferentiated liposarcoma (n = 11), followed by other sarcomas. Thirty patients were newly diagnosed, and 15 underwent surgery for localized recurrent disease. Thirty-two and 13 patients underwent wide and marginal resection, respectively. Surgical margins were negative in 12 patients and positive in 33 patients. Chemotherapy was administered before or after radiotherapy in 16 patients. The 2-year local control, progression-free survival, and overall survival rates after post-operative radiotherapy were 88%, 78%, and 93%, respectively. In patients with positive resection margins, doses of ≥ 60 Gy contributed to local control (p = 0.0002, log-rank test) and progression-free survival (p = 0.0033). Late grade 3 adverse events were observed in 7% of the patients. Post-operative radiotherapy for soft tissue sarcomas is safe and effective, with high doses (≥ 60 Gy) contributing to reduced recurrence among patients with positive resection margins.

    DOI: 10.1007/s42399-024-01648-8

    Scopus

    CiNii Research

  • 経直腸超音波ガイド下での経腟的アプローチによる組織内照射併用腔内照射 局所進行子宮頸癌患者30例の治療成績(Transvaginal approach combined intracavitary and interstitial brachytherapy assisted by transrectal ultrasound: results from 30 patients with locally advanced cervical cancer) 査読 国際誌

    Nakashima Takaaki, Matsumoto Keiji, Yoshitake Tadamasa, Wakiyama Hiroaki, Hisano Osamu, Uehara Ryuji, Takaki Masanori, Oshima Takeshi, Yahata Hideaki, Ishigami Kousei

    Japanese Journal of Radiology   42 ( 1 )   96 - 101   2024年1月   ISSN:1867-1071

     詳細を見る

    記述言語:英語   出版者・発行元:(公社)日本医学放射線学会  

    局所進行子宮頸癌(LACC)に対し、経直腸超音波(TRUS)ガイド下経腟的アプローチによる組織内照射併用腔内照射(IC/IS BT)を行い、有効性と安全性を後向きに調査した。外照射療法とTRUSガイド下で経腟アプローチによりIC/IS BTの治療を受けたLACC患者30例(年齢31~82歳)を調査対象とし、2年局所制御率(LC)、無増悪生存率(PFS)および全生存率(OS)をKaplan-Meier法で分析した。また、遅発性有害事象に基づきIC/IS BTの安全性についても評価した。その結果、経過観察期間の中央値は22ヵ月で、2年LC、PFSおよびOSはそれぞれ90%、61%、82%であった。また、IC/IS BT法に関連した重篤な合併症例はみられず、グレード3以上の遅発性有害事象としては、グレード4の結腸穿孔が認められた。以上より、経腟的アプローチによるTRUSガイド下でのIC/IS BTは、LACCにおいて、安全且つ良好な局所腫瘍制御が得られることが確認された。

  • Efficacy and Safety of Adjuvant Radiotherapy for Soft Tissue Sarcoma: A Two-Institution Retrospective Observational Study 査読

    Hisano O, Yoshitake T, Nomoto S, Matsumoto K, Wakiyama H, Uehara R, Takaki M, Oshima T, Matsumoto Y, Endo M, Nabeshima A, Matsunobu T, Maekawa A, Ishigami K

    SN Compr Clin Med   2024年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • 肺への体幹部定位放射線治療のための体内標的体積の定義における不確実性に関する検討(Investigation of uncertainty in internal target volume definition for lung stereotactic body radiotherapy) 査読 国際誌

    Nakanishi Daiki, Oita Masataka, Fukunaga Jun-ichi, Hirose Taka-aki, Yoshitake Tadamasa, Sasaki Motoharu

    Radiological Physics and Technology   16 ( 4 )   497 - 505   2023年12月   ISSN:1865-0333

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:(公社)日本放射線技術学会  

    3次元CT(3DCT)及び4次元CT(4DCT)により定義された体内標的体積(ITV)の有効性を評価し、治療時における腫瘍の呼吸性移動と比較した。2017年2月~2019年4月に肺上葉に非小細胞肺癌を有する患者5名(男性3名、女性2名、77~86歳)に対して48Gyで4分割の体幹部定位放射線治療(SBRT)を実施した。治療計画用の3DCT画像は呼気ピーク時及び吸気ピーク時の息止めで取得し、4DCT画像は自由呼吸下でのシネモードで取得した。シネ画像は照射時に電子的放射線治療照合装置を用いて取得した。tumor coverageは左右、前後及び頭尾方向の照射時に治療計画CT画像上のピーク間呼吸振幅が腫瘍可動域(±3SD)をどのようにカバーしているか評価した。頭尾方向における4DCTベースのITVは3DCTベースのITVと比べて平均tumor coverageが良好であった。また、4DCT用に照射野を設定する場合には体内マージンを考慮する必要があった。

  • Combination of Clinical Factors and Radiomics Can Predict Local Recurrence and Metastasis After Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer 査読 国際誌

    Isoyama-Shirakawa, Y; Yoshitake, T; Ninomiya, K; Asai, K; Matsumoto, K; Shioyama, Y; Kodama, T; Ishigami, K; Arimura, H

    ANTICANCER RESEARCH   43 ( 11 )   5003 - 5013   2023年11月   ISSN:0250-7005 eISSN:1791-7530

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Anticancer Research  

    Background/aim: Radiomics, which links radiological image features with patient prognoses, is expected to be applied for the prediction of the clinical outcomes of radiotherapy. We investigated the clinical and radiomic factors associated with recurrence patterns after stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC).

    Patients and methods: We retrospectively analyzed 125 patients with histologically confirmed NSCLC who underwent SBRT between April 2003 and June 2017 at our institution. A radiomic score was calculated from five radiomics features (histogram and texture features) selected using the LASSO Cox regression model. These features were extracted from the gross tumor volume (GTV) in three-dimensional wavelet decomposition CT images. We used univariate and multivariate analyses to determine the associations between local control (LC) time and metastasis-free survival (MFS), clinical factors (age, sex, performance status, operability, smoking, histology, and tumor diameter), and the radiomic score.

    Results: With a median follow-up of 37 months, the following 3-year rates were observed: overall survival, 80.9%; progression-free survival, 61.7%; LC, 75.1%, and MFS; 74.5%. In multivariate analysis, histology (squamous cell carcinoma vs. non-squamous cell carcinoma, p=0.0045), tumor diameter (>3 cm vs. ≤3 cm, p=0.039); and radiomic score (>0.043 vs. ≤0.043, p=0.042) were significantly associated with LC, and the radiomic score (>0.304 vs. ≤0.304, p<0.001) was significantly associated with MFS.

    Conclusion: Histology, tumor diameter, and radiomic score could be significant factors for predicting NSCLC recurrence patterns after SBRT.

    DOI: 10.21873/anticanres.16699

    Web of Science

    Scopus

    PubMed

  • Outcome of parameningeal head and neck rhabdomyosarcoma in adults: Kyushu Medical Oncology Group Study 査読

    Isobe, T; Tsuchihashi, K; Ueno, S; Taguchi, R; Ito, M; Nakano, M; Ariyama, H; Hanamura, F; Okumura, Y; Komoda, M; Esaki, T; Arita, S; Nio, K; Kusaba, H; Hashimoto, K; Yoshitake, T; Oda, Y; Akashi, K; Baba, E

    ANNALS OF ONCOLOGY   34   S1409 - S1409   2023年11月   ISSN:0923-7534 eISSN:1569-8041

     詳細を見る

    記述言語:英語  

    DOI: 10.1016/j.annonc.2023.09.205

    Web of Science

  • Multicenter Retrospective Study of Stereotactic Body Radiotherapy for Patients with Previously Untreated Initial Small Hepatocellular Carcinoma 査読

    Doi, Y; Nagata, Y; Matsumo, Y; Numata, K; Sasaki, R; Yamada, T; Igaki, H; Imagumbai, T; Katoh, N; Yoshitake, T; Shimizuguchi, T; Fujioka, D; Inoue, M; Koide, Y; Kimura, T; Ito, Y

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   117 ( 2 )   E293 - E293   2023年10月   ISSN:0360-3016 eISSN:1879-355X

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    PubMed

  • Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan 査読 国際誌

    Tsuchihashi, K; Ito, M; Arita, S; Kusaba, H; Kusano, W; Matsumura, T; Kitazono, T; Ueno, S; Taguchi, R; Yoshihiro, T; Doi, Y; Arimizu, K; Ohmura, H; Kajitani, T; Nio, K; Nakano, M; Oshima, K; Tamura, S; Shirakawa, T; Shimokawa, H; Uchino, K; Hanamura, F; Okumura, Y; Komoda, M; Isobe, T; Ariyama, H; Esaki, T; Hashimoto, K; Komune, N; Matsuo, M; Matsumoto, K; Asai, K; Yoshitake, T; Yamamoto, H; Oda, Y; Akashi, K; Baba, E

    BMC CANCER   23 ( 1 )   1046 - 1046   2023年10月   eISSN:1471-2407

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BMC Cancer  

    Background: Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the anatomic reason. PM-HNRMS has a poor prognosis in children. However, its clinical outcomes remain unclear in adults due to the rarity. Further, there is almost no detailed data about salvage therapy.

    Methods: We retrospectively examined the adult patients with PM-HNRMS treated at institutions belonging to the Kyushu Medical Oncology Group from 2009 to 2022. We evaluated the overall survival (OS) and progression-free survival (PFS) of the patients who received a first-line therapy. We also reviewed the clinical outcomes of patients who progressed against a first-line therapy and received salvage therapy.

    Results: Total 11 patients of PM-HNRMS received a first-line therapy. The characteristics were as follows: median age: 38 years (range 25 - 63 years), histology (alveolar/spindle): 10/1, and risk group (intermediate/high): 7/4. As a first-line therapy, VAC and ARST0431-based regimen was performed in 10 and 1 patients, respectively. During a first-line therapy, definitive radiation for all lesions were performed in seven patients. The median PFS was 14.2 months (95%CI: 6.0 - 25.8 months): 17.1 months (95%CI: 6.0 - not reached (NR)) for patients with stage I-III and 8.5 months (95%CI: 5.2 - 25.8 months) for patients with stage IV. The 1-year and 3-year PFS rates were 54.5% and 11.3% for all patients. Median OS in all patients was 40.8 months (95%CI: 12.1 months-NR): 40.8 months (95%CI: 12.1 - NR) for patients with stage I-III and NR for patients with stage IV. The 5-year OS rate was 48.5% for all patients. Among seven patients who received salvage therapy, three are still alive, two of whom remain disease-free for over 4 years after completion of the last therapy. Those two patients received multi-modal therapy including local therapy for all detected lesions.

    Conclusion: The cure rate of adult PM-HNRMS is low in spite of a first-line therapy in this study. Salvage therapy might prolong the survival in patients who received the multi-modal therapy including local therapy for all detected lesions.

    DOI: 10.1186/s12885-023-11528-4

    Web of Science

    Scopus

    PubMed

  • Deep learning model fusion improves lung tumor segmentation accuracy across variable training-to-test dataset ratios 査読

    Cui, YH; Arimura, H; Yoshitake, T; Shioyama, Y; Yabuuchi, H

    PHYSICAL AND ENGINEERING SCIENCES IN MEDICINE   46 ( 3 )   1271 - 1285   2023年9月   ISSN:2662-4729 eISSN:2662-4737

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Physical and Engineering Sciences in Medicine  

    This study aimed to investigate the robustness of a deep learning (DL) fusion model for low training-to-test ratio (TTR) datasets in the segmentation of gross tumor volumes (GTVs) in three-dimensional planning computed tomography (CT) images for lung cancer stereotactic body radiotherapy (SBRT). A total of 192 patients with lung cancer (solid tumor, 118; part-solid tumor, 53; ground-glass opacity, 21) who underwent SBRT were included in this study. Regions of interest in the GTVs were cropped based on GTV centroids from planning CT images. Three DL models, 3D U-Net, V-Net, and dense V-Net, were trained to segment the GTV regions. Nine fusion models were constructed with logical AND, logical OR, and voting of the two or three outputs of the three DL models. TTR was defined as the ratio of the number of cases in a training dataset to that in a test dataset. The Dice similarity coefficients (DSCs) and Hausdorff distance (HD) of the 12 models were assessed with TTRs of 1.00 (training data: validation data: test data = 40:20:40), 0.791 (35:20:45), 0.531 (31:10:59), 0.291 (20:10:70), and 0.116 (10:5:85). The voting fusion model achieved the highest DSCs of 0.829 to 0.798 for all TTRs among the 12 models, whereas the other models showed DSCs of 0.818 to 0.804 for a TTR of 1.00 and 0.788 to 0.742 for a TTR of 0.116, and an HD of 5.40 ± 3.00 to 6.07 ± 3.26 mm better than any single DL models. The findings suggest that the proposed voting fusion model is a robust approach for low TTR datasets in segmenting GTVs in planning CT images of lung cancer SBRT.

    DOI: 10.1007/s13246-023-01295-8

    Web of Science

    Scopus

    PubMed

  • Supramaximal Resection Can Prolong the Survival of Patients with Cortical Glioblastoma: A Volumetric Study 査読 国際誌

    Otsuji, R; Hata, N; Funakoshi, Y; Kuga, D; Togao, O; Hatae, R; Sangatsuda, Y; Fujioka, Y; Takigawa, K; Sako, A; Kikuchi, K; Yoshitake, T; Yamamoto, H; Mizoguchi, M; Yoshimoto, K

    NEUROLOGIA MEDICO-CHIRURGICA   63 ( 8 )   364 - 374   2023年8月   ISSN:04708105 eISSN:13498029

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:一般社団法人 日本脳神経外科学会  

    We aimed to retrospectively determine the resection rate of fluid-attenuated inversion recovery (FLAIR) lesions to evaluate the clinical effects of supramaximal resection (SMR) on the survival of patients with glioblastoma (GBM). Thirty-three adults with newly diagnosed GBM who underwent gross total tumor resection were enrolled. The tumors were classified into cortical and deep-seated groups according to their contact with the cortical gray matter. Pre-and postoperative FLAIR and gadolinium-enhanced T1-weighted imaging tumor volumes were measured using a three-dimensional imaging volume analyzer, and the resection rate was calculated. To evaluate the association between SMR rate and outcome, we subdivided patients whose tumors were totally resected into the SMR and non-SMR groups by moving the threshold value of SMR in 10% increments from 0% and compared their overall survival (OS) change. An improvement in OS was observed when the threshold value of SMR was 30% or more. In the cortical group (n = 23), SMR (n = 8) tended to prolong OS compared with gross total resection (GTR) (n = 15), with the median OS of 69.6 and 22.1 months, respectively (p = 0.0945). Contrastingly, in the deep-seated group (n = 10), SMR (n = 4) significantly shortened OS compared with GTR (n = 6), with median OS of 10.2 and 27.9 months, respectively (p = 0.0221). SMR could help prolong OS in patients with cortical GBM when 30% or more volume reduction is achieved in FLAIR lesions, although the impact of SMR for deep-seated GBM must be validated in larger co-horts.

    DOI: 10.2176/jns-nmc.2022-0351

    Web of Science

    Scopus

    PubMed

    CiNii Research

  • Supramaximal resectionは皮質神経膠腫患者の生存期間を延長させる 容積測定による研究(Supramaximal Resection Can Prolong the Survival of Patients with Cortical Glioblastoma: A Volumetric Study) 査読

    Otsuji Ryosuke, Hata Nobuhiro, Funakoshi Yusuke, Kuga Daisuke, Togao Osamu, Hatae Ryusuke, Sangatsuda Yuhei, Fujioka Yutaka, Takigawa Kosuke, Sako Aki, Kikuchi Kazufumi, Yoshitake Tadamasa, Yamamoto Hidetaka, Mizoguchi Masahiro, Yoshimoto Koji

    Neurologia medico-chirurgica   63 ( 8 )   364 - 374   2023年8月   ISSN:0470-8105

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本脳神経外科学会  

    膠芽腫患者を対象とした後ろ向き研究を実施し、FLAIR病変切除率を評価することで、supramaximal resection(SMR)の臨床効果について検討した。2006年12月~2018年8月に神経膠腫と診断された成人患者のうち、肉眼的全切除(GTR)が施行された成人33例(年齢中央値64歳、男性19例)を対象とした。評価項目は腫瘍切除率(手術前後のFLAIRおよびガドリニウム強調T1強調画像の腫瘍体積を3D画像体積分析装置により測定)、SMR率(0%から10%刻み)などとした。腫瘍を皮質灰白質との接触により、皮質群23例(SMR 8例、GTR 15例)、深在性群10例(SMR 4例、全切除6例)に分けて検討した。その結果、SMR閾値が30%以上の場合に全生存期間の改善が観察された。皮質群ではGTRと比較してSMRで全生存期間が延長する傾向が認められた(69.6ヵ月対22.1ヵ月)。一方、深在群ではGTRと比較してSMRで全生存期間が有意に短縮していた(10.2ヵ月対27.9ヵ月、p=0.0221)。以上から、FLAIR病変のsupramaximal resectionは神経膠腫患者の生存期間を延長可能であることが示された。

  • 治療歴のない初発小型肝細胞癌患者に対する体幹部定位放射線療法の多施設共同後ろ向き研究(Multicenter retrospective study of stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma) 査読 国際誌

    Doi Yoshiko, Nagata Yasushi, Matsumoto Yasuo, Numata Kazushi, Sasaki Ryu, Yamada Takashi, Igaki Hiroshi, Imagumbai Toshiyuki, Katoh Norio, Yoshitake Tadamasa, Shimizuguchi Takuya, Fujioka Den, Inoue Minoru, Koide Yutaro, Kimura Tomoki, Ito Yoshinori

    Hepatology Research   53 ( 8 )   749 - 760   2023年8月   ISSN:1386-6346

     詳細を見る

    記述言語:英語   出版者・発行元:John Wiley & Sons Australia, Ltd  

    2013年7月~2017年12月に日本の14施設で体幹部定位放射線療法(SBRT)を行った治療歴のない初発小型肝細胞癌(HCC)患者76例の83病変のうち、SBRT分割数が10超であった患者を除外後の73例の79病変を対象に、SBRTの有効性と安全性を評価した。年齢中央値は77歳(範囲50~89歳)、腫瘍サイズ中央値は23mm(範囲6~50mm)、照射線量中央値は5分割(範囲4~8分割)での40Gy(範囲35~60Gy)であった。追跡期間中央値は45ヵ月(範囲0~103ヵ月)で、3年後の全生存率、無再発生存率、局所再発の累積発生率はそれぞれ69.9%、57.9%、20.0%であった。グレード3以上の有害事象は4例(5.5%)で認められ(グレード3が3例、グレード4が1例)、グレード5の毒性を認めた患者はいなかった。標準治療が不適格の初発小型HCCに対し、SBRTは有望な治療法であることが示された。

  • Multicenter retrospective study of stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma 査読

    Doi, Y; Nagata, Y; Matsumoto, Y; Numata, K; Sasaki, R; Yamada, T; Igaki, H; Imagumbai, T; Katoh, N; Yoshitake, T; Shimizuguchi, T; Fujioka, D; Inoue, M; Koide, Y; Kimura, T; Ito, Y

    HEPATOLOGY RESEARCH   53 ( 8 )   749 - 760   2023年8月   ISSN:1386-6346 eISSN:1872-034X

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/hepr.13908

    Web of Science

    PubMed

  • Skeletal muscle area predicts the outcomes of non-small-cell lung cancer after trimodality therapy 査読

    Watanabe, K; Kinoshita, F; Takenaka, T; Nagano, T; Oku, Y; Kosai, K; Ono, Y; Haratake, N; Kohno, M; Kamitani, T; Yoshitake, T; Okamoto, T; Shimokawa, M; Ishigami, K; Yoshizumi, T

    INTERDISCIPLINARY CARDIOVASCULAR AND THORACIC SURGERY   36 ( 2 )   2023年2月   ISSN:15699285 eISSN:2753-670X

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Interdisciplinary cardiovascular and thoracic surgery  

    OBJECTIVES: Sarcopenia correlates with poor prognosis in various malignancies. However, the prognostic significance of sarcopenia remains to be determined in patients with non-small-cell lung cancer who undergo surgery after receiving neoadjuvant chemoradiotherapy (NACRT). METHODS: We retrospectively reviewed the patients with stage II/III non-small-cell lung cancer who underwent surgery following NACRT. The paravertebral skeletal muscle area (SMA) (cm2) at the 12th thoracic vertebra level was measured. We calculated the SMA index (SMAI) as SMA/squared height (cm2/m2). Patients were divided into low and high SMAI groups, and the association of SMAI with clinicopathological factors and prognosis was assessed. RESULTS: The patients' [men, 86 (81.1%)] median age was 63 (21-76) years. There were 106 patients including 2 (1.9%), 10 (9.4%), 74 (69.8%), 19 (17.9%) and 1 (0.9%) patients with stage IIA, IIB, IIIA, IIIB and IIIC, respectively. Of the patients, 39 (36.8%) and 67 (63.2%) were classified in the low and the high SMAI groups, respectively. Kaplan-Meier analysis showed that the low group had a significantly shorter overall survival and disease-free survival than the high group. Multivariable analysis identified low SMAI as an independent poor prognostic factor for overall survival. CONCLUSIONS: Pre-NACRT SMAI correlates with poor prognosis; therefore, assessing sarcopenia based on pre-NACRT SMAI may help determine optimal treatment strategies and suitable nutritional and exercise interventions.

    DOI: 10.1093/icvts/ivad020

    Web of Science

    Scopus

    PubMed

  • 【最新臨床肺癌学-診断・治療の最新動向-】治療 放射線治療 放射線治療における深層学習の応用

    塩山 善之, 二宮 健太, 廣瀬 貴章, 兒玉 拓巳, 吉武 忠正, 有村 秀孝

    日本臨床   80 ( 増刊8 最新臨床肺癌学 )   477 - 483   2022年12月   ISSN:0047-1852

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)日本臨床社  

  • 食道癌の化学放射線療法後の縦隔リンパ節再発に対し重粒子線治療が奏効した1例 査読

    吉満 凜吾, 吉武 忠正, 浅井 佳央里, 松本 圭司, 高木 正統, 篠藤 誠, 塩山 善之, 石神 康生

    臨床放射線   67 ( 12 )   1685 - 1690   2022年11月   ISSN:0009-9252

     詳細を見る

    担当区分:責任著者   記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:金原出版(株)  

    70歳代男性。胸部中部食道癌に対する化学放射線療法から7ヵ月後、縦隔リンパ節再発が認められた。FP療法を1コース施行するも効果なく、重粒子線治療を施行したところ、奏効した。最終治療から5年以上経過現在、再発や重篤な有害事象はみられない。

  • 食道疾患の診療 Ⅲ 食道癌の診療 20 食道癌に対する集学的治療-化学放射線療法 招待

    髙木 正統, 吉武 忠正, 石神 康生

    臨床消化器内科   37 ( 9 )   1154 - 1157   2022年8月   ISSN:0911601X eISSN:24332488

     詳細を見る

    記述言語:日本語   出版者・発行元:日本メディカルセンター  

    DOI: 10.19020/cg.0000002324

    CiNii Research

  • 【食道疾患の診療】食道癌の診療 食道癌に対する集学的治療 化学放射線療法

    高木 正統, 吉武 忠正, 石神 康生

    臨床消化器内科   37 ( 9 )   1154 - 1157   2022年8月   ISSN:0911-601X

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)日本メディカルセンター  

  • Relapse predictability of topological signature on pretreatment planning CT images of stage I non-small cell lung cancer patients before treatment with stereotactic ablative radiotherapy 査読 国際誌

    Kodama, T; Arimura, H; Shirakawa, Y; Ninomiya, K; Yoshitake, T; Shioyama, Y

    THORACIC CANCER   13 ( 15 )   2117 - 2126   2022年8月   ISSN:1759-7706 eISSN:1759-7714

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Thoracic Cancer  

    Background: This study aimed to explore the predictability of topological signatures linked to the locoregional relapse (LRR) and distant metastasis (DM) on pretreatment planning computed tomography images of stage I non-small cell lung cancer (NSCLC) patients before treatment with stereotactic ablative radiotherapy (SABR). Methods: We divided 125 primary stage I NSCLC patients (LRR: 34, DM: 22) into training (n = 60) and test datasets (n = 65), and the training dataset was augmented to 260 cases using a synthetic minority oversampling technique. The relapse predictabilities of the conventional wavelet-based features (WF), topology-based features [BF, Betti number (BN) map features; iBF, inverted BN map features], and their combined features (BWF, iBWF) were compared. The patients were stratified into high-risk and low-risk groups using the medians of the radiomics scores in the training dataset. Results: For the LRR in the test, the iBF, iBWF, and WF showed statistically significant differences (p < 0.05), and the highest nLPC was obtained for the iBF. For the DM in the test, the iBWF showed a significant difference and the highest nLPC. Conclusion: The iBF indicated the potential of improving the LRR and DM prediction of stage I NSCLC patients prior to undergoing SABR.

    DOI: 10.1111/1759-7714.14483

    Web of Science

    Scopus

    PubMed

  • Differences Between AcurosXB and AAA On Collimator Angle in VMAT-SBRT for Lung Tumor 査読

    Yamanaka, Y; Inoue, K; Suetsugu, Y; Tateishi, M; Hirose, T; Fukunaga, J; Yoshitake, T; Sasaki, T; Atsumi, K

    MEDICAL PHYSICS   49 ( 6 )   E964 - E964   2022年6月   ISSN:0094-2405 eISSN:2473-4209

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

  • Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study 査読

    Funakoshi, Y; Takigawa, K; Hata, N; Kuga, D; Hatae, R; Sangatsuda, Y; Fujioka, Y; Otsuji, R; Sako, A; Yoshitake, T; Togao, O; Hiwatashi, A; Iwaki, T; Mizoguchi, M; Yoshimoto, K

    WORLD NEUROSURGERY   159   E479 - E487   2022年3月   ISSN:1878-8750 eISSN:1878-8769

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:World Neurosurgery  

    Background: Controversies exist regarding the aggressive recurrence of glioblastoma after bevacizumab treatment. We analyzed the clinical impact of bevacizumab approval in Japan by evaluating the clinical course and relapse pattern in patients with glioblastoma. Methods: We included 100 patients with IDH-wild-type glioblastoma from September 2006 to February 2018 in our institution. The patients were classified into the pre-bevacizumab (n = 51) and post-bevacizumab (n = 49) groups. Overall, progression-free, deterioration-free, and postprogression survivals were compared. We analyzed the relapse pattern of 72 patients, whose radiographic progressions were evaluated. Results: Significant improvement in progression-free (pre-bevacizumab, 7.5 months; post-bevacizumab, 9.9 months; P = 0.0153) and deterioration-free (pre-bevacizumab, 8.5 months; post-bevacizumab, 13.8 months; P = 0.0046) survivals was seen. These survival prolongations were strongly correlated (r: 0.91, P < 0.0001). The nonenhancing tumor pattern was novel in the post-bevacizumab era (5 of 33). The presence of a nonenhancing tumor did not indicate poor postprogression survival (hazard ratio: 0.82 [0.26–2.62], P = 0.7377). The rate of early focal recurrence was significantly lower (P = 0.0155) in the post-bevacizumab (4 of 33) than in the pre-bevacizumab (18 of 39) era. There was a significant decrease in early focal recurrence after approval of bevacizumab in patients with unresectable tumors (P = 0.0110). The treatment era was significantly correlated with a decreased rate of early focal recurrence (P = 0.0021, univariate analysis; P = 0.0144, multivariate analysis). Conclusions: Approval of first-line bevacizumab in Japan for unresectable tumors may prevent early progression and clinical deterioration of glioblastoma without worsening the clinical course after relapse.

    DOI: 10.1016/j.wneu.2021.12.075

    Web of Science

    Scopus

    PubMed

  • Synergistic combination of a topologically invariant imaging signature and a biomarker for the accurate prediction of symptomatic radiation pneumonitis before stereotactic ablative radiotherapy for lung cancer: A retrospective analysis 査読 国際誌

    Ninomiya, K; Arimura, H; Yoshitake, T; Hirose, TA; Shioyama, Y

    PLOS ONE   17 ( 1 )   e0263292   2022年1月   ISSN:1932-6203

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PLoS ONE  

    Objectives We aimed to explore the synergistic combination of a topologically invariant Betti number (BN)-based signature and a biomarker for the accurate prediction of symptomatic (grade ≥2) radiation-induced pneumonitis (RP+) before stereotactic ablative radiotherapy (SABR) for lung cancer. Methods A total of 272 SABR cases with early-stage non-small cell lung cancer were chosen for this study. The occurrence of RP+ was predicted using a support vector machine (SVM) model trained with the combined features of the BN-based signature extracted from planning computed tomography (pCT) images and a pretreatment biomarker, serum Krebs von den Lungen-6 (BN+KL-6 model). In all, 242 (20 RP+ and 222 RP–(grade 1)) and 30 cases (8 RP+ and 22 RP–) were used for training and testing the model, respectively. The BN-based features were extracted from BN maps that characterize topologically invariant heterogeneous traits of potential RP+ lung regions on pCT images by applying histogram- and texture-based feature calculations to the maps. The SVM models were built to predict RP+ patients with a BN signature that was constructed based on the least absolute shrinkage and selection operator logistic regression model. The evaluation of the prediction models was performed based on the area under the receiver operating characteristic curves (AUCs) and accuracy in the test. The performance of the BN+KL-6 model was compared to the performance based on the BN, conventional original pCT, and wavelet decomposition (WD) models. Results The test AUCs obtained for the BN+KL-6, BN, pCT, and WD models were 0.825, 0.807, 0.642, and 0.545, respectively. The accuracies of the BN+KL-6, BN, pCT, and WD models were found to be 0.724, 0.708, 0.591, and 0.534, respectively. Conclusion This study demonstrated the comprehensive performance of the BN+KL-6 model for the prediction of potential RP+ patients before SABR for lung cancer.

    DOI: 10.1371/journal.pone.0263292

    Web of Science

    Scopus

    PubMed

  • 放射線治療における深層学習の応用

    塩山 善之, 廣瀬 貴章, 吉武 忠正, 有村 秀孝

    日本臨牀 最新臨床肺癌学 ―診断・治療の最新動向― V. 治療   80 (増刊号8)   477 - 483   2022年

     詳細を見る

    記述言語:日本語  

    CiNii Research

  • The Evolving Genomic Landscape of Esophageal Squamous Cell Carcinoma Under Chemoradiotherapy. 査読 国際誌

    Hirata H, Niida A, Kakiuchi N, Uchi R, Sugimachi K, Masuda T, Saito T, Kageyama SI, Motomura Y, Ito S, Yoshitake T, Tsurumaru D, Nishimuta Y, Yokoyama A, Hasegawa T, Chiba K, Shiraishi Y, Du J, Miura F, Morita M, Toh Y, Hirakawa M, Shioyama Y, Ito T, Akimoto T, Miyano S, Shibata T, Mori M, Suzuki Y, Ogawa S, Ishigami K, Mimori K.

    Cancer Res   2021年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma. 招待 査読 国際誌

    Funakoshi Y, Hata N, Takigawa K, Arita H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Sako A, Umehara T, Yoshitake T, Togao O, Hiwatashi A, Yoshimoto K, Iwaki T, Mizoguchi M.

    Cancer Med.   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Automated approach for segmenting gross tumor volumes for lung cancer stereotactic body radiation therapy using CT-based dense V-networks. 査読 国際誌

    Cui Y, Arimura H, Nakano R, Yoshitake T, Shioyama Y, Yabuuchi H.

    J Radiat Res.   2021年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation? 査読 国際誌

    Ieiri K, Shiota M, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Iwai H, Shiga KI, Yokomizo A, Yoshitake T, Shioyama Y, Ishigami K, Terashima H, Eto M.

    Urol Oncol.   2020年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Radiomic prediction of radiation pneumonitis on pretreatment planning computed tomography images prior to lung cancer stereotactic body radiation therapy. 査読 国際誌

    Hirose TA, Arimura H, Ninomiya K, Yoshitake T, Fukunaga JI, Shioyama Y.

    Sci Rep.   2020年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Similar-cases-based planning approaches with beam angle optimizations using water equivalent path length for lung stereotactic body radiation therapy. 査読 国際誌

    Haseai S, Arimura H, Asai K, Yoshitake T, Shioyama Y.

    Radiol Phys Technol.   2020年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Observer uncertainties of soft tissue-based patient positioning in IGRT. 査読 国際誌

    Hirose TA, Arimura H, Fukunaga JI, Ohga S, Yoshitake T, Shioyama Y.

    2020年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide. 査読 国際誌

    Hata N, Mizoguchi M, Kuga D, Hatae R, Akagi Y, Sangatsuda Y, Amemiya T, Michiwaki Y, Fujioka Y, Takigawa K, Suzuki SO, Yoshitake T, Togao O, Hiwatashi A, Yoshimoto K, Iihara K.

    J Neurooncol.   2020年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Survival and ocular preservation in a long-term cohort of Japanese patients with retinoblastoma. 査読 国際誌

    Ueda T, Koga Y, Yoshikawa H, Tanabe M, Yamana K, Oba U, Nakashima K, Ono H, Ichimura T, Hasegawa S, Kato W, Kobayashi T, Nakayama H, Sakai Y, Yoshitake T, Ohga S, Oda Y, Suzuki S, Sonoda KH, Ohga S.

    BMC Pediatr.   2020年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma. 招待 査読 国際誌

    Nakashima T, Nonoshita T, Hirata H, Inoue K, Nagashima A, Yoshitake T, Asai K, Shioyama S.

    In Vivo.   2020年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Radical Radiotherapy for Hemodialysis Patients with Esophageal Cancer 招待 査読 国際誌

    Takaki M, Ohga S, Yoshitake T, Asai K, Hirata H, Matake K, Nomoto S, Honda H

    Fukuoka Acta Med.   2019年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • 膠芽腫の放射線治療後の増悪形式とその無増悪期間、生存期間との関連について 査読

    吉武忠正, 塩山善之, 中村和正, 野元諭, 樋渡昭雄, 吉浦敬, 平田秀紀, 松本俊一, 溝口昌弘, 庄野禎久, 佐々木富男, 本田浩

    臨床放射線   54 ( 5 )   2009年7月

     詳細を見る

    記述言語:日本語  

  • Erythema multiforme and Stevens-Johnson syndrome following radiotherapy 査読 国際誌

    Yoshitake T, Nakamura K, Shioyama Y, Sasaki T, Ooga S, Abe M, Urashima Y, Urabe K, Terashima H, Honda H

    Radiat Med   25 ( 1 )   2007年7月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Bilateral ovarian leiomyomas: CT and MRI features 査読 国際誌

    Yoshitake T, Asayama Y, Yoshimitsu K, Irie H, Aibe H, Tajima T, Nishie A, Nakayama T, Kakihara D, Ariyoshi K, Kaneki E, Honda H

    Abdom Imaging   30 ( 1 )   117 - 119   2005年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00261-004-0202-7

  • A machine vision system with CCD cameras for patient positioning in radiotherapy: a preliminary report 査読

    Yoshitake T, Nakamura K, Shioyama Y, Sasaki T, Ohga S, Yamaguchi T, Toba T, Anai S, Terashima H, Honda H

    Fukuoka Igaku Zasshi   96 ( 12 )   2005年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Fitz-Hugh-Curtis syndrome: CT所見の検討 査読

    吉武忠正, 西江昭弘, 松浦隆志, 高橋信, 吉満研吾, 入江裕之, 相部仁, 田嶋強, 篠崎賢治, 中山智博, 柿原大輔, 本田浩

    日本医学放射線学会誌   63 ( 6 )   2003年7月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

▼全件表示

書籍等出版物

  • 2010別冊 代表的照射野とCT上のターゲット

    吉武忠正, 塩山善之(担当:共著)

    2010年12月 

     詳細を見る

    担当ページ:p150-151   記述言語:日本語   著書種別:学術書

    リポジトリ公開URL: http://hdl.handle.net/2324/1001488120

  • Future of SBRT with Photon and Charged Particles

    Yoshitake T., Matsunobu A., Shioyama Y.

    Stereotactic Body Radiation Therapy: Principles and Practices, Second Edition  2023年1月    ISBN:9789819939787, 9789819939770

     詳細を見る

    The previous chapters have described the evolution of the SBRT with photon beams to date, and further evolution in many respects is expected in the future. In this chapter, we describe what we can expect for the future of SBRT using photons and charged particles. In SBRT using photons, irradiation at extremely high dose rates, called FLASH radiotherapy is expected to lead to less side effects while maintaining the therapeutic effect on the tumor, and is expected to be widely used in clinical applications in the future. Other promising developments include the concurrent combination of immunotherapy and SBRT, identification of predictors of risk of recurrence such as radiomics and liquid biopsy, and the application of SBRT to palliative care and benign diseases are also expected. SBRT using charged particles has been studied for localized malignancies such as lung cancer, hepatocellular carcinoma, and oligometastases. In recent years, charged-particle therapy techniques have made significant progress, including pencil-beam scanning irradiation and intensity-modulated particle therapy (IMPT), which have been followed by the steady development of new treatment techniques such as proton beam FLASH therapy, LET distribution optimization therapy, and intensity-modulated combined particle therapy (IMPACT). Further studies and developments will enable this therapeutic technique to be used in clinical practice.

    DOI: 10.1007/978-981-99-3978-7_23

    Scopus

  • Stereotactic Body Radiation Therapy; Principles and Practices, Yasushi Nagata Editor

    吉武 忠正, 塩山 善之

    Springer  2023年    ISBN:9789819939787

     詳細を見る

    総ページ数:325  

    CiNii Research

講演・口頭発表等

  • High pre-treatment neutrophil-to-lymphocyte ratio predicts poor survival in patients with glioblastoma treated with radiotherapy and temozolomide 国際会議

    @Tadamasa Yoshitake, @Saiji Ohga, @Satoshi Nomoto, @Toshihiro Yamaguchi, @Kaori Asai, @Hidenari Hirata, @Osamu Hisano, @Yushi Motomura, @Akio Hiwatashi, @Koji Yoshimoto, @Hiroshi Honda

    ASTRO2016  2016年9月 

     詳細を見る

    開催年月日: 2016年9月

    記述言語:英語   会議種別:口頭発表(一般)  

    開催地:Boston   国名:アメリカ合衆国  

  • Incidence of radiation pneumonitis after multiple courses of stereotactic body radiation therapy for lung cancer patients 国際会議

    吉武 忠正

    ASTRO  2014年9月 

     詳細を見る

    開催年月日: 2014年9月

    記述言語:英語  

    開催地:サンフランシスコ   国名:アメリカ合衆国  

  • Stereotactic body radiation therapy for primary lung cancers which were clinically diagnosed without pathological confirmation: a single-institution experience 国際会議

    Tadamasa Yoshitake, Yoshiyuki Shioyama, Katsumasa Nakamura, Tomonari Sasaki, Ohga Saiji, Hideki Hirata, Hiroshi Honda

    RSNA  2012年11月 

     詳細を見る

    開催年月日: 2012年11月

    記述言語:英語   会議種別:口頭発表(一般)  

    国名:アメリカ合衆国  

    Purpose Pathological diagnosis of small lung lesions is sometimes difficult in inoperable patients. The purpose of the present study was to evaluate the outcome of stereotactic body radiotherapy (SBRT) for small lung lesions that are clinically diagnosed as primary lung cancer without pathologic confirmation. Materials and methods Between April 2003 and July 2011, 82 patients with small pulmonary lesions clinically diagnosed as primary lung cancer were treated with SBRT in Kyushu University Hospital. The median age of the 66 patients was 75 years (range 51- 92 years). Forty four patients were male, and 38 were female. The median tumor size was 19 mm (range 8-40 mm). Thin-section CT findings for these pulmonary lesions showed solid nodules and ground-glass opacity (GGO) nodules in 53 and 29 patients, respectively. The radiation dose was 48 Gy in 4 fractions in all patients. Results Median follow-up was 20 months (range 6-83 months). Recurrence was observed in 13 (15.9%) patients (local failure, 6; regional failure, 5; distant metastases, 6) with solid nodules. There was no recurrence in 29 patients with GGO nodules. Two patients died of recurrence and 10 patients died from other diseases. Local control rate, cause-specific survival and overall survival at 3 years were 88%, 98% and 79%, respectively. Two (2.4%) patients and 5 (6.1%) patients had grade 2 radiation pneumonitis and grade 2 rib fracturing, respectively. There were no adverse effects of grade 3 or greater during follow-up. Conclusions SBRT is to be considered a safe and effective treatment option for small lung lesions clinically diagnosed as primary lung cancer without pathologic confirmation, especially in patients with GGO nodules.

  • Dosimetric evaluation in stereotactic radiotherapy for pulmonary ground-glass opacity nodules: The relationship with calculation algorithm and dose prescription methods. 国際会議

    Yoshitake T, Shioyama Y, Nakamura K, Ohga S, Nonoshita T, Ohnishi K, Asai K, Matsumoto K, Hirata H, Honda H.

    Radiological Society of North America  2010年12月 

     詳細を見る

    開催年月日: 2010年11月 - 2010年12月

    会議種別:口頭発表(一般)  

    開催地:Chicago   国名:アメリカ合衆国  

  • 在宅酸素療法中の原発性肺癌患者に対する体幹部定位放射線治療

    吉武 忠正, 塩山 善之, 大賀 才路, 野々下 豪, 大西 かよ子, 浅井 佳央里, 松本 圭司, 中村和正, 平田秀紀, 本田 浩

    日本放射線腫瘍学会学術大会第23回学術大会  2010年11月 

     詳細を見る

    開催年月日: 2010年11月

    開催地:千葉県浦安市   国名:日本国  

  • 九州大学病院における寡分割照射の取り組みと治療システム

    吉武忠正

    第20回九州放射線治療システム研究会  2022年2月 

     詳細を見る

    開催年月日: 2022年2月

    記述言語:日本語  

    開催地:福岡市   国名:日本国  

  • 再発膠芽腫に対するベバシズマブ併用定位放射線治療の治療成績

    吉武忠正, 浅井佳央里, 松本圭司, 白川友子, 稻盛真人, 中島孝彰, 樋渡昭雄, 佐々木智成, 西江昭弘, 秦暢宏, 塩山善之

    日本放射線腫瘍学会 第32回学術大会  2019年11月 

     詳細を見る

    開催年月日: 2019年11月

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:名古屋市   国名:日本国  

  • 肺定位放射線治療における近似症例を利用した治療計画支援システムの検証

    @吉武忠正,@野元 諭,@大賀才路,@浅井佳央里,@松本圭司,@平田秀成,@中島孝彰,@佐々木智成,@本田浩

    日本放射線腫瘍学会 第31回学術大会  2018年10月 

     詳細を見る

    開催年月日: 2018年10月

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:京都市   国名:日本国  

  • Grade 2-3髄膜腫に対する高精度放射線治療成績

    @吉武忠正、@大賀才路、@野元 諭、@浅井佳央里、@平田秀成、@中島孝彰、@上原隆治、@髙木正統、@佐々木智成、@吉本幸司、@本田 浩

    日本放射線腫瘍学会第30回学術大会  2017年11月 

     詳細を見る

    開催年月日: 2017年11月

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:大阪市   国名:日本国  

  • A preliminary result of computer-aided radiotherapy planning system using previous similar cases for stereotactic body radiotherapy

    @Tadamasa Yoshitake, @Satoshi Nomoto, @Saiji Ohga, @Toshihiro Yamaguchi, @Kaori Asai, @Hidenari Hirata, @Osamu Hisano, @Yushi Motomura, @Daisuke Maruoka, @Tomonari Sasaki, @Hiroshi Honda

    第76回日本医学放射線学会総会  2017年4月 

     詳細を見る

    開催年月日: 2017年4月

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:横浜市   国名:日本国  

  • イブニングセミナー:放射線科医としての楽しみ 招待

    吉武忠正

    ミッドサマーセミナー2011  2011年7月 

     詳細を見る

    開催年月日: 2011年7月

    会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

    開催地:神戸市   国名:日本国  

▼全件表示

MISC

▼全件表示

所属学協会

  • 日本癌治療学会

  • 日本医学放射線学会

  • 日本放射線腫瘍学会

学術貢献活動

  • 座長(Chairmanship)

    第173日本医学放射線学会九州地方会  ( Japan ) 2011年6月

     詳細を見る

    種別:大会・シンポジウム等 

共同研究・競争的資金等の研究課題

  • 深層学習を応用した肺癌放射線治療後の肺臓炎重症度予測と治療法最適化システムの開発

    2020年 - 2023年

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      詳細を見る

    担当区分:研究分担者  資金種別:科研費

  • 放射線治療用臓器抽出エンジンの開発に向けた、放射線治療データ収集

    2019年12月 - 2021年3月

      詳細を見る

    資金種別:その他産学連携による資金

  • 化学放射線耐性を生む食道癌ゲノム・免疫応答のクローン進化の解明

    2019年 - 2021年

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      詳細を見る

    担当区分:研究分担者  資金種別:科研費

  • 膵癌克服に向けた重粒子線治療と深層学習の融合による集学的治療アルゴリズムの開発

    2019年 - 2021年

    日本学術振興会  科学研究費助成事業  特別推進研究

      詳細を見る

    担当区分:研究分担者  資金種別:科研費

  • 深層学習を用いた転移性脳腫瘍の予後予測と放射線治療方針決定システムの開発

    研究課題/領域番号:18K07718  2018年 - 2020年

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      詳細を見る

    担当区分:研究代表者  資金種別:科研費

  • 肺癌の個別化ゲノム医療に向けた定位放射線治療感受性のバイオマーカー探索

    2017年 - 2021年

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      詳細を見る

    担当区分:研究分担者  資金種別:科研費

  • I期非小細胞肺がんに対するTS-1併用体幹部定位放射線治療の認容性試験

    2017年 - 2019年

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      詳細を見る

    担当区分:研究分担者  資金種別:科研費

  • 肺・肝以外の諸臓器における定位放射線治療の効果と安全性の評価

    2016年 - 2020年

    日本学術振興会  科学研究費助成事業  基盤研究(B)

      詳細を見る

    担当区分:研究分担者  資金種別:科研費

  • 近似症例検索エンジンを用いた放射線治療計画支援システムの開発

    研究課題/領域番号:26461894  2014年 - 2016年

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      詳細を見る

    担当区分:研究代表者  資金種別:科研費

▼全件表示

教育活動概要

  • <医学部学生>
    ・講義
      医学部2年生:医工学入門(放射線の原理)
      医学部4年生:系統医学III(放射線医学 放射線治療I・II、臨床腫瘍学 腫瘍の放射線治療、緩和ケア 放射線治療)
    ・ベッドサイド
      スライドを用いたレクチャーを行い、放射線治療の基礎知識、放射線物理学、放射線物理学、有害事象、粒子線治療について解説する。その後、放射線治療部門で、実際の治療室・機器を見学しながら治療について説明を行う。その後実際の放射線治療計画システムを用いて、放射線治療計画実習を行い放射線治療計画について解説を行う。
    ・クリニカルクラークシップ
      放射線治療の臨床において、指導医に同行してもらい、患者への診察、説明を見学する。また放射線治療計画装置を用いて、放射線治療計画の実際を学んでもらう。各種カンファレンスにも同行してもらい、他科との連携についても学んでもらう。
    ・臨床研修医
      放射線治療について理解し、患者・家族への放射線治療についての説明できるように指導する。実際の患者に対して、放射線治療計画を一緒に行う。病棟担当医として放射線治療中の患者の全身管理・支持療法について指導している。

担当授業科目

  • 系統医学III(臨床腫瘍学) 腫瘍の放射線療法

    2022年10月 - 2023年3月   後期

  • 系統医学III(緩和ケア) 放射線治療

    2022年10月 - 2023年3月   後期

  • 系統医学III(放射線医学) 放射線治療 II

    2022年10月 - 2023年3月   後期

  • 系統医学III(放射線医学) 放射線治療 I

    2022年10月 - 2023年3月   後期

  • 放射線治療学総論

    2022年4月 - 2022年9月   前期

  • 医工学入門 放射線の原理

    2022年4月 - 2022年9月   前期

  • 系統医学III(緩和ケア) 放射線治療

    2021年10月 - 2022年3月   後期

  • 医工学入門 放射線の原理

    2021年4月 - 2021年9月   前期

  • 放射線治療学総論

    2021年4月 - 2021年9月   前期

  • 系統医学III(放射線医学) 放射線治療 I

    2021年4月 - 2021年9月   前期

  • 系統医学III(放射線医学) 放射線治療 II

    2021年4月 - 2021年9月   前期

  • 系統医学III(臨床腫瘍学) 腫瘍の放射線療法

    2020年10月 - 2021年3月   後期

  • 系統医学III(放射線医学) 放射線治療 I

    2020年10月 - 2021年3月   後期

  • 系統医学III(緩和ケア) 放射線治療

    2020年10月 - 2021年3月   後期

  • 系統医学III(放射線医学) 放射線治療 II

    2020年10月 - 2021年3月   後期

  • 医工学入門 放射線の原理

    2020年4月 - 2020年9月   前期

  • 放射線治療学総論

    2019年4月 - 2019年9月   前期

  • 放射線治療学総論

    2018年4月 - 2018年9月   前期

▼全件表示

その他教育活動及び特記事項

  • 2022年  その他特記事項  がんプロコース選択大学院生に対する講義「放射線治療総論」

     詳細を見る

    がんプロコース選択大学院生に対する講義「放射線治療総論」

社会貢献・国際連携活動概要

  • 2014年より日本放射線腫瘍学会の代議員を務めている。
    また同学会の、がん放射線治療推進委員会、放射線治療専門医制度委員会に所属し、社会貢献活動を行っている。

社会貢献活動

  • 不明

    ボストン・サイエンティフィック ジャパン株式会社/(株)朝日カルチャーセンター  2021年10月

     詳細を見る

    対象:社会人・一般, 学術団体, 企業, 市民団体, 行政機関

    種別:講演会

専門診療領域

  • 生物系/医歯薬学/内科系臨床医学/放射線科学

臨床医資格

  • 認定医

    日本放射線腫瘍学会

  • 専門医

    日本医学放射線学会

  • 認定医

    日本癌治療学会

医師免許取得年

  • 1999年

特筆しておきたい臨床活動

  • ・外来診療:九州大学病院放射線科外来にて放射線治療に関する患者診療を行っている。 ・入院診療:九州大学病院放射線科の病棟において、放射線治療中の患者の回診や、治療方針決定、担当医への指導などを行っている。 ・管理:平成31年度より原発不明がん部会部会長として、部会を開催している。